INTRODUCTION
Chemoimmunotherapy (CIT) has been the standard first-line treatment for patients with chronic lymphocytic leukemia (CLL). 1 In the last several years major strides have been made in understanding the biology of CLL and fortunately, several of these discoveries are making their way into the clinics. [2] [3] [4] [5] These include novel CD20 monoclonal antibodies (mAb) (ofatumumab, obinutuzumab), 6 Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib), 3 PI3kinase inhibitors (Idelalisib), 5 Bcl-2 inhibitors (ABT-199) and several others. 7 Lenalidomide, an immunomodulatory drug, has also been studied in CLL, both in the relapsed and in the first-line setting. 8 In this review, we summarize the available clinical data, in the first-line setting, with both the chemotherapy and the targeted therapy approaches in patients with CLL.
INDICATIONS FOR TREATMENT
Most patients with CLL do not need treatment at the time of the diagnosis of CLL.
However, the majority will ultimately require treatment during their lifetime. Assessment of For personal use only. on May 10, 2017 . by guest www.bloodjournal.org From note that the median age of diagnosis of CLL in the United States is 72 years, and the average time to first treatment is 4-5 years from the time of diagnosis. However, most clinical trials in the first-line setting have enrolled younger patients.
FIRST-LINE TREATMENT

A) Intensive CIT Eligible Patients [non-del(17p)]
The current standard first-line treatment for this group of patients is CIT with fludarabine, cyclophosphamide, and rituximab (FCR). 12 Tam et al. reported long-term outcomes of 300 patients treated first-line with FCR at the MD Anderson Cancer Center (MDACC). 12, 13 The achieved. In patients with a partial response (PR) or better, the median progression-free survival (PFS) was 80 months. Older age (≥70 years) was associated with a lower rate of achieving CR (51%). Twenty-six percent of patients did not complete the recommended six courses of the FCR therapy. 12 The major cause of premature discontinuation of therapy was persistent cytopenia (majority neutropenia), noted in almost half of the patients who discontinued therapy.
Early discontinuation of therapy was significantly associated with advanced Rai stage, age >65 years, creatinine > 1.4 mg/dL, hemoglobin <11 g/dL, and β 2-microglobulin >4 mg/dL. Dose reductions were more common in patients older than 60 years of age.
The GCLLSG compared outcomes of FCR vs. fludarabine/cyclophosphamide (FC) in a phase III trial (CLL8 trial Bendamustine has also been evaluated as first-line treatment for patients with CLL.
Fischer et al. reported on the outcomes of 117 patients, median age 64 years (range, 34-78), with untreated CLL who received treatment with bendamustine and rituximab. 15 Eligibility criteria included creatinine clearance >30 mL/min. Bendamustine was administered at a dose of 90 mg/m2 on days 1 and 2 combined with 375 mg/m2 rituximab on day 0 of the first course, and 500 mg/m2 on day 1 during subsequent courses, for up to six courses. The ORR was 88% with a CR rate of 23%. The median PFS was 34 months. Notably, 35% of the patients had a creatinine clearance ≤ 70 mL/min (these patients are typically excluded from the GCLLSG FCRbased studies) and these patients did equally well as compared to patients with a creatinine 25, 26 an alternate purine analogue (pentostatin), 27, 28 and an alternate anti-CD20 mAb (ofatumumab) 29, 30 in patients with CLL (see Table 1 identified by the GCLLSG to be associated with a worse PFS in patients receiving first-line FCR. 14 Importantly, 60% of patients with mutated IGHV who received first-line FCR have remained free of disease progression beyond 10 years (compared to only 10% for patients with unmutated IGHV). These data point towards a possible future therapeutic strategy where the CIT approach would be reserved for patients with mutated IGHV. The current standard first-line treatment for this group of patients is CIT with chlorambucil and an anti-CD20 antibody. 6 Hillmen et al. reported results of a phase II study of the combination of chlorambucil and rituximab (NCRI CLL208 trial). 34 A total of 100 patients were treated with a median age of 70 years. The ORR was 84% with a CR rate of 10%. The median PFS was 24 months. Foa et al. reported outcomes of 85 patients who received first-line treatment with chlorambucil and rituximab, followed by rituximab maintenance vs. observation. 35 The median age was 70 years. The ORR was 82% with a CR rate of 17%. The median PFS was 35 months. There was a trend towards longer PFS for patients receiving rituximab maintenance.
Minimal residual disease (MRD) quantification and long-term outcomes
Obinutuzumab is a humanized type II CD20 mAb with a glycoengineered Fc domain that leads to increased direct antibody induced cell death, enhanced antibody-dependent cellular cytotoxicity (ADCC), and lower complement dependent cytotoxicity (CDC) than the type I CD20 mAb, rituximab. 36, 37 In preclinical studies, obinutuzumab was more effective than rituximab in Bcell depletion and inhibiting growth of human lymphomas in animal models. 36, 37 In the GCLLSG CLL11 trial, previously untreated patients with CLL with coexisting conditions (total CIRS score >6 and/or creatinine clearance 30-69 mL/min) were randomly assigned on a 1:2:2 basis to receive chlorambucil monotherapy, chlorambucil plus rituximab, or chlorambucil plus obinutuzumab. 6 ,38 A total of 781 patients were enrolled with a median age of 73 years. Patients with del(17p) or TP53 gene mutation have poor outcomes with conventional CIT regimens such as FCR, in part due to lack of wild-type p53 function, an important pathway for mediating cytotoxicity of purine analogs. 13, 14, 40 In the GCLLSG CLL8 trial, only 1 of the 22 (5%) such patients treated on the FCR arm achieved a CR with a median PFS of only 11.3 months. 14 For
Similarly, in the GCLLSG first-line BR trial, none of the 8 patients with del(17p) achieved CR and the median PFS was only 7.9 months. 15 In a recent retrospective analysis, the MDACC group reported outcomes of 63 patients with del(17p) receiving first-line treatment (mainly FCRbased regimens) with a median PFS of only 14 months. 41 Alemtuzumab, a humanized anti-CD52 monoclonal antibody, acts via a p53 independent pathway and was thought to be an attractive strategy for patients with del(17p). 42 Hillmen et al. conducted a phase III randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil in the first-line treatment of patients with CLL. 43 In the subset of patients with del(17p) who were treated on the alemtuzumab arm, the median PFS was only 10.7 months, not dissimilar from the FCR first-line data. 43 In an attempt to increase the efficacy of alemtuzumab, two recent studies evaluated the combination of alemtuzumab and corticosteroids. In the UK CLL206 trial, the use of alemtuzumab with high-dose pulse methylprednisolone as first-line treatment for patients with del(17p) (n=17) resulted in a high ORR of 88% (CR 65%) but the median PFS was only 18.3 months. 44 The French/German CLL20 trial combined alemtuzumab with dexamethasone followed by consolidation either with alemtuzumab or with an allogeneic stem cell transplant (allo-SCT). 45 Forty-two patients with del(17p) received first-line therapy with alemtuzumab and dexamethasone in this trial with an ORR of 97% (CR 21%) and a median PFS of 32.8 months.
Consolidation with allo-SCT may have contributed to the improved outcomes for this group of patients. However, due to the introduction of novel therapies (such as ibrutinib, detailed below), potential toxicities with alemtuzumab (CMV reactivation etc.), and the withdrawal of alemtuzumab from the market (available only directly from the manufacturer), alemtuzumab has limited role in the management of patients with CLL.
Ibrutinib is an oral, selective and irreversible inhibitor of BTK and is the current standard first-line therapy for patients with del(17p) (see the section on novel therapies for details). with CLL who received rituximab and granulocyte-macrophage colony-stimulating factor (GM-CSF) as initial therapy. 47 The median age was 73 years. The ORR was 59% with a median PFS of 15 months. Flinn et al. examined the role of ofatumumab monotherapy in the first-line setting in patients who were either >65 or in younger patients who had declined fludarabine-based treatment. 48 A total of 77 patients were enrolled with a median age of 72 years. Ofatumumab was given weekly for 8 weeks with an initial dose of 300 mg followed by either 2000 mg (cohort 1) or 1000 mg (cohort 2). Maintenance therapy with ofatumumab (every 2 months) for 2 years was also given. The ORR for cohorts 1 and 2 was 55% (5% CR) and 36% (4% CR), respectively. The PFS at 15 months for cohort 1 was 74%. Flynn et al. examined the role of obinutuzumab monotherapy in untreated patients with CLL (GAGE trial). 49 A total of 80 patients (median age 67 years) were treated at either the 2000mg or 1000mg dose level. The ORR was higher in the 2000mg cohort (67% ORR, 21% CR/CRi) compared to the 1000mg cohort (49% ORR, 5% CR/CRi). 58, 59 The median age was 60 years (range, 33-78). The original study design used a starting lenalidomide dose of 10 mg daily (21 days out of a 28-day cycle). However, significant toxicities (tumor lysis, cytopenias) were noted in first two enrolled patients; the study was then amended to decrease the starting dose to 2.5 mg daily, with a target daily dose of 10 mg (dose escalation to 25 mg was permitted for non-responders). The median daily dose received was 15 mg. In the original report, an ORR of 56% was noted with no CR. 58 In an updated analysis, the authors reported an improved ORR of 72% with 20% CR rate. 59 Similar to the MDACC study, the responses improve over time and the best response is often delayed; the median time to best response in this study was 18 months. The 3-year PFS and OS were 65% and 85%, respectively. 59 Grade 3-4 neutropenia and thrombocytopenia were common (76% and 28%, respectively). The MDACC group recently reported preliminary results of the combination of lenalidomide and rituximab as first-line therapy for patients with CLL. 60 The treatment consisted of rituximab 375 mg/m 2 given weekly for 4 weeks then monthly during months 3-12 and lenalidomide 10 mg PO/day from day 9 onwards continuously. Forty-eight patients were evaluable with a median age of 66 years (range, 42-79). The ORR was 83% with a CR rate of B-cell receptor (BCR) activation plays a crucial role in the pathogenesis of CLL. 61, 62 BTK is a non-receptor tyrosine kinase of the Tec kinase family and plays a crucial role in BCR signaling. 63 Ibrutinib is an oral, selective and irreversible inhibitor of BTK. It forms a specific bond with the cysteine-481 of BTK. 64 Ibrutinib has been extensively studied in patients with relapsed or refractory CLL with a very high ORR and improved PFS and OS compared to ofatumumab in a randomized phase III trial (RESONATE trial). [2] [3] [4] Ibrutinib is FDA approved for patients with relapsed/refractory CLL and for patients with del(17p). 3 There are limited data reported so far with ibrutinib in the first-line setting. O'Brien et al. reported on the outcomes of 31 patients with CLL/small lymphocytic lymphoma (SLL) who received ibrutinib monotherapy in the first-line setting. 65 The median age was 71 years (range, 65-84). As this was a first-line trial, the frequency of del(17p) and del(11q) were low (6% and 3%, respectively). After a median follow-up of 35 months, an ORR of 84% was noted with 23% attaining CR, 55% PR, and 6% PR-L. 4 The 30-month PFS was 96% and OS was 97%. It is important to note that most patients will develop lymphocytosis after initiating ibrutinib. This is an expected finding with ibrutinib and other BCR inhibitors and it generally resolves over the course of 6-9 months with continued ibrutinib treatment. Development of lymphocytosis does not appear to be detrimental to the long-term clinical outcomes. 66 A recent study from the National Heart, Lung, and Blood Institute reported on the outcomes of 35 patients with untreated CLL with del(17p) or TP53 mutation who received treatment with ibrutinib. 67 The median age was 62 years (range, ). An impressive ORR of 97% was noted with 12% attaining CR, 70% PR, and 15% PR with lymphocytosis (PR-L). The median time to CR was 48 weeks. The 2-year PFS was 91%. These data compare quite favorably to the median PFS of only 11 months noted with CIT in the first-line setting for patients with del(17p). 14 In addition, in the relapsed setting, the median PFS for patients with 17p
NOVEL THERAPIES IN THE FIRST-LINE SETTING
deletion with ibrutinib monotherapy is approximately 28 months 4 ; these data in the relapsed setting are much superior to that seen with CIT even in the first-line setting for patients with del(17p). Based on these data, the FDA and the EMA approved ibrutinib for all patients with del(17p). Ibrutinib is the current standard first-line therapy for patients with del(17p).
PI3K-delta is critical for activation, proliferation and survival of B cells and is hyperactive in many B-cell malignancies, including CLL. 68 Idelalisib is a potent and selective inhibitor of PI3K-delta and is approved by the FDA in combination with rituximab for patients with relapsed/refractory CLL where rituximab monotherapy would be considered appropriate. 5 The idelalisib and rituximab combination is also approved for the first-line treatment of patients with del(17p) by the EMA, but not the FDA. As with ibrutinib, the majority of studies with idelalisib have been conducted in patients with relapsed or refractory CLL, 5 and there are limited data in the first-line setting. In a recent report, idelalisib monotherapy (150 mg BID) was given as firstline therapy to older patients (≥65 years) with CLL/SLL. 69 A total of 37 patients (median age 70 years) were treated. Fourteen percent of the patient had del(17p). In the 27 evaluable patients, an ORR of 81% (all PR/PR-L) was noted. The most frequent grade ≥ 3 treatment-related adverse events (AEs) included rash 3%, diarrhea 3%, and pneumonia 5%. Pneumonitis was observed in 2 patients. Results from idelalisib in combination with rituximab in the first-line setting for older patients (≥65 years) with CLL/SLL have also been reported. 70 A total of 64 patients were enrolled with a median age of 71 years (range, 65-90). The ORR was 97% with a CR rate of 19%. There were 9 patients with del(17p)/TP53 mutation, all of whom responded (3 CR, 6 PR). However, toxicities were common with this regimen; the important grade ≥ 71, 72 and a more intact immune system in the first-line setting may have contributed to the increased toxicities.
CONCLUSIONS
As detailed above, the therapy for CLL is undergoing a major transformation at this time. 
